Abstract:Purpose: Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL), a member of the TNF family, can selectively induce cancer cell death while sparing normal cells. However, the application of TRAIL-based antitumor therapies has been hindered due to drug resistance. Alternol is a new compound isolated from microbial fermentation that possesses antitumor activity in different tumors. In our research, we discovered that alternol can sensitize TRAIL-induced apoptosis in renal carcinoma cells (RCCs). Materials and Methods: Cytotoxic activity was measured by MTT assay. Apoptosis was probed using the PI/annexin V method. Real-time PCR and western blot were used to test the levels of mRNA and protein, respectively. Luciferase assay was used to investigate whether CHOP regulated the expression of death receptor (DR) 5 through transcription. A xenogeneic tumor transplantation model was used to evaluate the anticancer effects of alternol/TRAIL in vivo . Results: When the mechanisms were investigated, we discovered that alternol increased DR5 expression. DR5 knockdown by siRNA eliminated the enhanced effect of alternol on TRAIL-mediated apoptosis. Alternol reduced the expression of antiapoptotic proteins and increased the levels of proapoptotic proteins. Moreover, alternol increased the level of CHOP, which is necessary for the enhancing effect of alternol on TRAIL-induced apoptosis, given that downregulation of CHOP abrogated the synergistic effect. DR5 upregulation induced by alternol required the production of reactive oxygen species (ROS). Removing ROS inhibited the induction of DR5 and blocked the antiapoptotic proteins induced by alternol. Conclusion: Taken together, our research suggested that alternol increased TRAIL-mediated apoptosis via inhibiting antiapoptotic proteins and upregulating DR5 levels via ROS generation and the CHOP pathway.

Alteronol Enhances the Anti-tumor Activity and Reduces the Toxicity of High-Dose Adriamycin in Breast Cancer

Protective and Sensitive Effects of Melatonin Combined with Adriamycin on ER+ (estrogen Receptor) Breast Cancer.

Alternol Exerts Prostate‐selective Antitumor Effects Through Modulations of the AMPK Signaling Pathway

Ophiobolin-O Reverses Adriamycin Resistance Via Cell Cycle Arrest and Apoptosis Sensitization in Adriamycin-Resistant Human Breast Carcinoma (MCF-7/ADR) Cells

First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models

Synergistic Effects of TOR Combined with EADM on Growth and Apoptosis in Human Lung Cancer Cell Lines A549 and H1299

Synergy and Attenuation Effects of Dihydromyricetin on Tumor-Bearing Mice Affected by Breast Cancer Treated with Chemotherapy

Prevention of Adriamycin-Induced Drug-Resistance of Leukemia Cells by Α-Tocopheryl Succinate and Arsenic Trioxide

Natural compound Alternol exerts a broad anti-cancer spectrum and a superior therapeutic safety index in vivo

Study on the Administration Method of Combining Tetrandrine with Adriamycin to Reverse Drug-Resistance of Leukemia

Dichloroacetate enhances adriamycin-induced hepatoma cell toxicity in vitro and in vivo by increasing reactive oxygen species levels

Synergistic nanoparticulate drug combination overcomes multidrug resistance, increases efficacy, and reduces cardiotoxicity in a nonimmunocompromised breast tumor model

Inhibitory Effect of Combined Herceptin and Adriamycin on Human Breast Cancer Cells

Amentoflavone-loaded nanoparticles enhanced chemotherapy efficacy by inhibition of AKR1B10

Arsenic Trioxide Reduces Drug Resistance to Adriamycin in Leukemic K562/A02 Cells Via Multiple Mechanisms.

AB928, a Dual Antagonist of the A2aR and A2bR Adenosine Receptors, Leads to Greater Immune Activation and Reduced Tumor Growth when Combined with Chemotherapy

Alternol Sensitizes Renal Carcinoma Cells to TRAIL-Induced Apoptosis

Dual Inhibition of Ornithine Decarboxylase and A1 Adenosine Receptor Efficiently Suppresses Breast Tumor Cells

Natural Product Toosendanin Reverses the Resistance of Human Breast Cancer Cells to Adriamycin As a Novel PI3K Inhibitor

Synergistic Antitumor Effects of Liposomal Honokiol Combined with Adriamycin in Breast Cancer Models.

Antitumor effects of curcumin combining with adriamycin in vitro